Abstract
Despite millennia of therapeutic plant use, deliberate exploitation of Cannabis‘s diverse biomedical potential has only recently gained attention. Bioactivity studies focus mainly on cannabidiol (CBD) and tetrahydrocannabinol (THC) with limited information about the broader cannabinome’s “minor phytocannabinoids”. In this context, our research targeted the synthesis of minor cannabinoids containing a lateral chain with 3 or 4 carbon atoms, focusing on cannabigerol (CBG) and cannabichromene (CBC) analogues. Using known and innovative strategies, we achieved the synthesis of 11 C3 and C4 analogues, five of which were inhibitors of skin inflammation, with the CBG-C4 ester derivative emerging as the most potent compound.
Similar articles
-
The structurally diverse phytocannabinoids cannabichromene, cannabigerol and cannabinol significantly inhibit amyloid β-evoked neurotoxicity and changes in cell morphology in PC12 cells.Basic Clin Pharmacol Toxicol. 2024 Mar;134(3):293-309. doi: 10.1111/bcpt.13943. Epub 2023 Sep 25.PMID: 37697481
-
Synthetic Pathways to Non-Psychotropic Phytocannabinoids as Promising Molecules to Develop Novel Antibiotics: A Review.Pharmaceutics. 2023 Jul 5;15(7):1889. doi: 10.3390/pharmaceutics15071889.PMID: 37514074 Free PMC article. Review.
-
Cannabidiol and Minor Phytocannabinoids: A Preliminary Study to Assess Their Anti-Melanoma, Anti-Melanogenic, and Anti-Tyrosinase Properties.Pharmaceuticals (Basel). 2023 Apr 26;16(5):648. doi: 10.3390/ph16050648.PMID: 37242431 Free PMC article.
-
Synthetic Strategies for Rare Cannabinoids Derived from Cannabis sativa.J Nat Prod. 2022 Jun 24;85(6):1555-1568. doi: 10.1021/acs.jnatprod.2c00155. Epub 2022 Jun 1.PMID: 35648593 Review.
-
Plant-derived cannabinoids modulate the activity of transient receptor potential channels of ankyrin type-1 and melastatin type-8.J Pharmacol Exp Ther. 2008 Jun;325(3):1007-15. doi: 10.1124/jpet.107.134809. Epub 2008 Mar 19.PMID: 18354058
LinkOut – more resources
-
Full Text Sources
-
Research Materials
-
Miscellaneous